MoH x BioLabs Accelerator Program

Powered by the Ministry of Health and BioLabs USA

Saudi Arabia is launching a bold new chapter in its biotech journey — with the debut of its first international accelerator program for life sciences startups, developed in partnership between the Ministry of Health and BioLabs USA, one of the world’s most respected innovation platforms for biotech entrepreneurship.

This initiative marks BioLabs’ first program in the MENA region, bringing world-class acceleration to Saudi innovators and reinforcing the Kingdom’s commitment to unlocking homegrown scientific talent.

Discover more

Visit the Accelerator Showcase inside the Saudi Pavilion (Booth #3265) at BIO 2025 to meet the founders and explore opportunities for partnership and co-development.

About the Program

This 7-month accelerator is designed to support eight high-potential Saudi startups in scaling scientific ideas into globally competitive ventures. The program kicked off at Tufts Launchpad | BioLabs in Boston with a high-profile event during BIO 2025.

Startups will benefit from a full spectrum of support, including:

Tailored mentorship from global biotech experts, investors, and founders
A personalized needs assessment via one-on-one strategy sessions with BioLabs coaches
Workshops and webinars on biotech business development, go-to-market strategy, and regulatory readiness
Mentor and investor matching through BioLabs’ extensive international network
Boston immersion week, featuring curated site visits, closed-door sessions with biotech leaders, and a final Demo Day to pitch to global VCs and industry partners

Through this platform, Saudi startups gain not only expertise and exposure, but also a launchpad to global partnerships, validation, and investment.

Meet the 8 Saudi Startups Shaping the Future of Biotech

These eight startups represent the next generation of Saudi biotech leadership – deeply rooted in science, ready to scale globally, and backed by a national system that believes in their potential.

Plansulin

Pioneering affordable, plant-based insulin using precision agriculture and synthetic biology, Plansulin transforms plants into biofactories. Their AI-powered platform optimizes protein yield and design, enabling scalable, cost-effective insulin and industrial enzyme production. At the intersection of sustainability and health equity, Plansulin is redefining biomanufacturing for a better future.

PhageTech

Addressing antibiotic resistance in food systems, PhageTech is developing a bacteriophage-based spray that safely eliminates harmful bacteria in poultry without harming beneficial microbes. Their sustainable, biodegradable solution enhances food safety at the source – supporting global health, biosecurity, and a cleaner agricultural future.

NanoPalm

NanoPalm is revolutionizing genetic therapies through AI-engineered, organ-targeted lipid nanoparticles (pLNPs). Their proprietary EnsaliX platform enables ultra-stable, fridge-stable, and tissue-specific delivery of mRNA and gene therapies – overcoming the limitations of traditional systems and opening new frontiers in precision medicine.

cellNUA

Harnessing honeybee biology, cellNUA develops de novo nanomolecules for next-generation vaccines and antivirals. Their Beemar platform translates honeybee immune intelligence into human therapeutics for infectious diseases like COVID-19, malaria, and dengue – fusing comparative genomics with glycomics to deliver nature-inspired innovation.

SAGEbio

SAGEbio is advancing localized vaccine and therapeutic protein development through a novel antigen platform co-developed with KAUST. With its lead COVID-19 vaccine entering Phase 1 trials in 2025, SAGEbio is boosting regional biomanufacturing and pandemic preparedness while developing alternatives to monoclonal antibodies using high-affinity protein scaffolds.

KaRama Bio

KaRama Bio is tackling pediatric health inequity with a non-invasive diagnostic platform that detects early biomarkers of allergies and immune deficiencies using biosamples like hair, stool, and saliva. Powered by mass spectrometry and machine learning, KaRama offers early, scalable, and affordable screening – redefining preventive care for children.

MammoStem

MammoStem is developing autologous mammary stem cell therapies to restore breast tissue post-surgery. By reprogramming breast epithelial cells, MammoStem enables personalized tissue regeneration for both oncologic and cosmetic applications, while offering a breakthrough platform for breast disease research and drug discovery.

Novo Genomics

A precision medicine leader, Novo Genomics operates one of Saudi Arabia’s most advanced NGS labs, offering WES, WGS, NIPT, and proprietary polygenic risk scores (PRS) tailored to Arab populations. By integrating tech transfer, AI-powered analytics, and microbiome platforms, Novo is driving scalable, data-driven healthcare across the Kingdom and beyond.

Get in touch to find out more

Book a meeting at the Pavilion, ask a question, or connect with the attending delegates.

Book a Meeting Contact Us